An email has been sent to your address with instructions for changing your password.
There is no user registered with this email.
Sign Up
To create a free account, please fill out the form below.
Thank you for signing up!
A confirmation email has been sent to your email address. Please check your email and follow the instructions in the message to complete the registration process. If you do not receive the email, please check your spam folder or contact us for assistance.
Welcome to our platform!
Oops!
Something went wrong while trying to create your new account. Please try again and if the problem persist, Email Us to receive support.
Scholar Rock to Present New Preclinical Data on its Targeted Approach to the LTBP-TGFβ1 Complex for Anti-Fibrotic Therapy at the 2022 FASEB Science Research Conference
Scholar Rock (NASDAQ: SRRK) announced new data on its selective TGFβ1 antibody, which inhibits proTGFβ1 activation linked to extracellular matrix proteins. This data shows reduced TGFβ1 signaling and fibrosis in preclinical models, suggesting a safe treatment for fibrotic diseases like Alport syndrome and scleroderma. The findings will be presented at the 2022 FASEB Science Research Conference in Ireland on July 21, highlighting Scholar Rock's innovative approach to treating serious diseases driven by protein growth factors.
Positive
Presentation of new data on selective TGFβ1 antibody could enhance treatment options for fibrotic diseases.
Potential reduction of fibrosis and immune-mediated side effects demonstrated in preclinical models.
Negative
None.
CAMBRIDGE, Mass.--(BUSINESS WIRE)--
Scholar Rock (NASDAQ: SRRK), a Phase 3, clinical-stage biopharmaceutical company focused on the treatment of serious diseases in which protein growth factors play a fundamental role, today announced the company will present new data that highlight the development of its highly selective, context-dependent TGFβ1 antibody that inhibits proTGFβ1 activation selectively in the context of its extracellular matrix presenting partner, latent TGFβ binding protein (“LTBP”; the target is collectively identified as “LTBP-TGFβ1”). The data show reduction of TGFβ1 signaling and reduction of fibrosis in relevant preclinical models in vivo. These findings will be presented in an oral and poster presentation at the 2022 FASEB Science Research Conference (SRC), taking place between July 17–21, 2022 in Malahide, Ireland.
“TGFβ1 plays a complex role in human disease, including fibrosis progression and immune regulation. Our earlier work established the isoform-selective approach to TGFb1 inhibition,” said Gregory Carven, Ph.D., Chief Scientific Officer of Scholar Rock. “This new research extends this idea further, showing that highly selective antibodies that inhibit TGFβ1 associated with specific extracellular matrix proteins can distinguish between the profibrotic and immunomodulatory activities of TGFβ1, and could potentially provide a safe and effective way to treat a wide range of fibrotic diseases—such as Alport syndrome, scleroderma or idiopathic pulmonary fibrosis—with a lower potential for immune-mediated side-effects.”
Data being featured at FASEB SRC will be made available in the Publications & Posters section of Scholar Rock’s website after the presentation:
Oral Presentation: Selective Targeting of Matrix-Associated TGFBeta1 as an Attractive Approach for Anti-Fibrotic Therapy
Presenter: Rohan Manohar, Ph.D., Associate Director of Discovery Biology at Scholar Rock Session: TGF-β Superfamily: Signaling in Development and Disease
Time: July 21, 9:45 a.m. CET
About Scholar Rock Scholar Rock is a clinical-stage biopharmaceutical company focused on the discovery and development of innovative medicines for the treatment of serious diseases in which signaling by protein growth factors plays a fundamental role. Scholar Rock is creating a pipeline of novel product candidates with the potential to transform the lives of patients suffering from a wide range of serious diseases, including neuromuscular disorders, cancer, and fibrosis. Scholar Rock’s approach to targeting the molecular mechanisms of growth factor activation enabled it to develop a proprietary platform for the discovery and development of monoclonal antibodies that locally and selectively target these signaling proteins at the cellular level. By developing product candidates that act in the disease microenvironment, the Company intends to avoid the historical challenges associated with inhibiting growth factors for therapeutic effect. Scholar Rock believes its focus on biologically validated growth factors may facilitate a more efficient development path. For more information, please visit www.ScholarRock.com or follow Scholar Rock on Twitter (@ScholarRock) and LinkedIn (https://www.linkedin.com/company/scholar-rock/). Investors and others should note that we communicate with our investors and the public using our company website www.scholarrock.com, including, but not limited to, company disclosures, investor presentations and FAQs, Securities and Exchange Commission filings, press releases, public conference call transcripts and webcast transcripts, as well as on Twitter and LinkedIn. The information that we post on our website or on Twitter or LinkedIn could be deemed to be material information. As a result, we encourage investors, the media and others interested to review the information that we post there on a regular basis. The contents of our website or social media shall not be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended.
Scholar Rock® is a registered trademark of Scholar Rock, Inc.
Forward-Looking Statements
This press release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements regarding Scholar Rock’s future expectations, plans and prospects, including without limitation, Scholar Rock’s expectations regarding its growth, strategy, and progress and indication selection and development timing, the ability of any product candidate to perform in humans in a manner consistent with earlier nonclinical, preclinical or clinical trial data, and the potential of its product candidates and proprietary platform. The use of words such as “may,” “might,” “could,” “will,” “should,” “expect,” “plan,” “anticipate,” “believe,” “estimate,” “project,” “intend,” “future,” “potential,” or “continue,” and other similar expressions are intended to identify such forward-looking statements. All such forward-looking statements are based on management's current expectations of future events and are subject to a number of risks and uncertainties that could cause actual results to differ materially and adversely from those set forth in or implied by such forward-looking statements. These risks and uncertainties include, without limitation, Scholar Rock’s ability to provide the financial support, resources and expertise necessary to identify and develop product candidates on the expected timeline, the data generated from Scholar Rock’s nonclinical and preclinical studies and clinical trials, and Scholar Rock’s ability to manage expenses and to obtain additional funding when needed to support its business activities, as well as those risks more fully discussed in the section entitled "Risk Factors" in Scholar Rock’s Quarterly Report on Form 10-Q for the quarter ended March 31, 2022, as well as discussions of potential risks, uncertainties, and other important factors in Scholar Rock’s subsequent filings with the Securities and Exchange Commission. Any forward-looking statements represent Scholar Rock’s views only as of today and should not be relied upon as representing its views as of any subsequent date. All information in this press release is as of the date of the release, and Scholar Rock undertakes no duty to update this information unless required by law.
What new data is Scholar Rock presenting regarding TGFβ1?
Scholar Rock is presenting data on a highly selective TGFβ1 antibody that inhibits proTGFβ1 activation, showing reduced TGFβ1 signaling and fibrosis in preclinical models.
When and where will Scholar Rock present its findings?
Scholar Rock will present its findings at the 2022 FASEB Science Research Conference in Ireland on July 21, 2022.
What diseases could benefit from Scholar Rock's new antibody research?
The research could potentially benefit patients with fibrotic diseases such as Alport syndrome, scleroderma, and idiopathic pulmonary fibrosis.
How does Scholar Rock’s approach differ from traditional therapies?
Scholar Rock’s approach focuses on selectively targeting TGFβ1 associated with specific extracellular matrix proteins, aiming to provide effective treatments with fewer side effects.
What is the significance of the presented data at the FASEB conference?
The significance lies in its potential to lead to safer and more effective therapies for fibrotic diseases, addressing the complex roles of TGFβ1 in human health.
